SynthesisLupus science & medicine2026
Prevalence and incidence of interstitial lung diseases in systemic lupus erythematosus: systematic review and meta-analyses.
Synthesis in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOur objective is to estimate the prevalence and incidence of interstitial lung diseases (ILDs) among adults with systemic lupus erythematosus (SLE) and to explore possible differences in reported prevalence and incidence of SLE-ILDs between clinical observational and register-based studies.
methodEMBASE, MEDLINE, Cochrane Library and Scopus were searched for eligible studies investigating SLE-ILDs prevalence and/or incidence. Risk of bias was assessed using the Joanna Briggs Institute Prevalence Critical Appraisal Tool. Data were extracted in a predefined Excel spreadsheet by two reviewers independent and blinded to each other. Pooled weighted prevalences and incidences were calculated with corresponding 95% CIs, visualised in forest plots. Heterogeneity was assessed with I
resultsNinety-eight studies comprising 155 964 participants were included in the systematic review and meta-analyses. The pooled weighted SLE-ILDs prevalence was 11.0% (9.0% to 13.0%), with substantial heterogeneity (I²=99.9%), and 18% when identifying SLE-ILDs with chest high-resolution CT (HRCT) scans. Clinical observational studies reported a higher prevalence of 25.0% (19.0% to 31.0%) compared with register-based studies 7.0% (5.0% to 8.0%). The incidence analysis was based on three registry-based studies and estimated an incidence of 4.9 per 1000 person-years (-0.5 to 10.3) with substantial heterogeneity (I² = 99.8%).
conclusionILDs appear to be a prevalent manifestation in SLE with a pooled prevalence estimate of 11.0%, although this estimate should be interpreted with caution due to substantial heterogeneity across studies. HRCT-based studies reported a higher prevalence (18.0%), suggesting that diagnostic modality influences prevalence estimates. The incidence estimate (4.9 per 1000 person-years) should be interpreted as exploratory because it was based on only three registry-based studies. Overall, the findings suggest that ILD may be more common in SLE than previously assumed, highlighting the importance of awareness of pulmonary manifestations. We found the prevalence to be higher in clinical observational studies than register-based studies. PROSPERO REGISTRATION NUMBER: CRD420250642237.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.